Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as panHer
BMS-599626 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 MTD Study | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-599626 | DRUG | - |
| panHer | DRUG | Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached. |
Inclusion Criteria: * Signed written informed consent * Available for periodic follow-up * Life expectancy of at least 3 months * ECOG performance status score 0-1 * Histologic or cytologic diagnosis of a primary malignancy of breast, ovarian, bladder, gastric, non small cell lung or colon origin *...
BMS-599626 is an investigational small molecule being studied in adults with HER2 or EGFR expressing advanced solid malignancies. It was evaluated in a Phase 1 dose-escalation study in patients with these biomarker-selected tumors. It is not an approved therapy; it remains in clinical development for oncology indications.
BMS-599626 targets HER2 and EGFR, two receptor tyrosine kinases that drive growth signaling in certain solid tumors. Because it acts on both receptors, the clinical program selected patients whose tumors express HER2 or EGFR. This dual targeting is the basis for its evaluation in advanced solid malignancies.
BMS-599626 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the compound in patients with HER2 or EGFR expressing advanced solid malignancies.
BMS-599626 is in Phase 1 development. Its only recorded clinical study was a Phase 1 dose-escalation trial that has completed. The drug is investigational and has not been approved for any indication.
BMS-599626 was studied in one Phase 1 trial, NCT00207012, titled MAD Refractory: Solid Tumor QD w/o Break. That study enrolled 45 adults with HER2 or EGFR expressing advanced solid malignancies in France and Spain. It was an uncontrolled, non-randomized, open-label trial and is now completed, with no active trials ongoing.
Yes. BMS-599626 was studied in a biomarker-selected population, enrolling only patients whose advanced solid malignancies expressed HER2 or EGFR. The Phase 1 trial NCT00207012 used this expression criterion for entry and enrolled 45 adults across sites in France and Spain.